Biosimilar Workload At FDA: Policy Development Far Exceeds Application Review
Executive Summary
Even as applications themselves remain low burden, intense policy efforts put pressure on user fees.
You may also be interested in...
Biosimilar User Fee Negotiations Won't Start Until 2016
Mid-December kick-off meeting puts emerging user fee program on much later track than others.
Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
New draft Q&A and three final guidances from FDA offer pros and cons for sponsors of biosimilar applications.
How To Get A Meeting With FDA: Guidance Describes Formal Meetings For Biosimilars
FDA’s fourth biosimilars-related guidance describes the formal meeting process for sponsors with products in development; the process will require extensive requests and information packages.